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Background: Guidance for postabortion care (PAC) is established for the ﬁrst trimester but limited in the second
trimester. Objectives: To establish evidence-based recommendations for PAC in the second trimester. Search
strategy:Medline, POPLINE, and the Cochrane Central Register of Controlled Trials were searched with terms
related to second-trimester PAC, including fetal demise, rupturedmembranes, and incomplete abortion. The ref-
erence lists of retrieved articles were also searched. Selection criteria: Clinical trials and comparative studies of
women presenting in the second trimester (12–28 weeks) were included if more than 50% of participants met
PAC criteria or if outcomes for PAC were analyzed separately. Data collection and analysis: Data were extracted
from included studies. When interventions in at least two articles were comparable, a meta-analysis was per-
formed. Main results: Overall, 17 studies of 1419 women met inclusion criteria. Misoprostol given vaginally,
sublingually, or buccally was associated with shorter expulsion times than was oral misoprostol. Additionally,
200 μg ofmisoprostol wasmore effective than lower doses. Pretreatmentwithmifepristone decreased expulsion
time. Misoprostol was more effective than oxytocin. Conclusion:Misoprostol with or without mifepristone is an
effective treatment for second-trimester PAC. Theminimummisoprostol dose is 200 μg vaginally, sublingually, or
buccally every 6–12 hours.
© 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ltd. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Postabortion care (PAC) is the comprehensive treatment of women
presenting after spontaneous or induced, safe or unsafe abortion. PAC
includes several key components: community and service provider
partnerships, counseling, treatment of incomplete abortionwith uterine
evacuation, management of complications, contraception, and repro-
ductive health services [1]. Following unsafe abortion, PAC services
reduce maternal morbidity and mortality.
Evidence-based guidelines [2,3] exist to support medical manage-
ment and vacuum aspiration for incomplete abortion in women
with a uterine size less than 13 weeks of pregnancy. However, many
women in countries with restricted abortion access present later in
pregnancy with fetal demise, ruptured membranes, retained placenta,
hemorrhage, a foreign body, or infectious complications resulting from
unsafe or self-induced abortion. These women could receive inconsis-
tent care from different providers in obstetrics and gynecology wards
or emergency departments. Magnitude studies from Sub-Saharan, 27515, USA. Tel.: +1 919 960
cology and Obstetrics. PublishedAfrica and Southeast Asia show high rates of hospital presentation for
PAC in the second trimester: 17% of women presenting for PAC in
Cambodia are in the second trimester [4], whereas this rate is 35% in
Malawi [5] and 41% in Kenya [6].
As the pregnancy duration increases, so does the risk of complica-
tions [7]. Creating evidence-based guidance for PAC in the second tri-
mester could reduce harm for women who need PAC at a later stage
in pregnancy. The aim of the present review was to establish recom-
mendations for women needing second-trimester PAC.
2. Materials and methods
The review was prepared in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines [8] and included the following review protocol.
2.1. Search strategy
Medline (January 1, 1946, to December 31, 2013), POPLINE (January
1, 1927, to December 31, 2013), and Cochrane Central Register of Con-
trolled Trials (January 1, 1898 to December 31, 2013) were searched
with the term “‘pregnancy, second trimester [MeSH Terms]’ AND ‘fetalby Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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ous abortion ORmissed abortion OR miscarriage OR abortion’”. The ref-
erence lists of retrieved articles were searched for nonindexed citations.
There were no language criteria.
2.2. Inclusion criteria
In the anticipation that randomized controlled trials of the manage-
ment of inevitable or incomplete abortion in the second trimester would
be scarce, nonrandomized trials and comparative cohort studies were
also included. The review included studies of women presenting in the
second trimester (12–28 weeks of pregnancy). Because second-trimester
PAC has not yet been clinically deﬁned, it was deﬁned for the purposes
of the present review as care forwomenpresenting after induced or spon-
taneous abortion in the second trimester who needed uterine evacuation.
Thus, studieswere included inwhichwomenpresentedwith inevitable or
incomplete abortion including fetal demise, ruptured membranes,
retained placenta, or retained fetal tissue. If the study had amixed popula-
tion of both PAC and induced abortion without a PAC indication, it was
included only if 50% or more of the population met the criteria for PAC.
If less than 50% of the study population were PAC patients, the study
was included if outcomes for PAC were analyzed separately. Termination
of pregnancy for fetal anomalies was considered as induced abortion.
If the study included both ﬁrst- and second-trimester pregnancies
but reported the second-trimester data separately, the second-
trimester data were extracted and included in the review. If the study
contained both second- and third-trimester pregnancies, all data were
included if more than 50% of the women had a second-trimester preg-
nancy. Studies were excluded if they did not specify the pregnancy
duration/uterine size.
In terms of interventions, the present review included studies that
focused on WHO-recommended methods for second-trimester abor-
tion or induction of labor appropriate for low-resource settings:
misoprostol-based regimens and/or dilation and evacuation (D&E) or
oxytocin [2,9]. If a WHO-recommended treatment was compared with
outdated techniques (including instillation, ethacridine, or other prosta-
glandin preparations), the study was not included.
2.3. Outcomes
The primary outcome was effectiveness, measured as time to suc-
cessful pregnancy expulsion. For medical management, it was expected
that effectiveness would be expressed as either time from initiation of
medications to fetal expulsion or as expulsion within 24 and 48 hours.
Because expulsion time is clinically relevant for women, providers,
and health facilities, this outcome was used as the primary outcome if
reported. Secondary outcomes were complications, adverse effects,
rates of incomplete expulsion or retained placenta, and complications
such as infection, hemorrhage, transfusion, or unplanned surgery.
2.4. Data collection and analysis
The ﬁrst and second reviewers (A.G.M. and L.B.) reviewed all articles
and determinedwhich studies met the inclusion criteria. In cases of dis-
agreement, a third reviewer (A.E.) judgedwhether the inclusion criteria
were met. If the information in the original study was insufﬁcient, that
study’s author was contacted for clariﬁcation. The ﬁrst and second
reviewers independently extracted data on design, participants, inter-
ventions, outcomes, and risk of bias from included studies. Any variance
was resolved by mutual agreement.
For randomized controlled trials, the risk of biaswas evaluated using
Cochrane methodology [10], which includes measures for the conceal-
ment of randomization and allocation, the blinding of participants and
study personnel, the blinding of outcome assessment, and the com-
pleteness of the outcome data. Studies were judged to have a low,
high, or unclear risk of bias. For cohort studies, the Newcastle–OttawaScale [11] was used; this scale assigns points for the selection and com-
parability of the study groups and for the ascertainment of the out-
comes, and is judged on a nine-point scale.
When the interventions in two or more articles were comparable,
RevMan version 5.2 (Cochrane Collaboration, Oxford, UK) was used to
perform ameta-analysis. This was only possible for the route of admin-
istration of misoprostol (vaginal versus oral).
Because most studies did not have comparable design features,
interventions, or outcomes, they could not be combined for meta-
analysis. If this was the case, individual study outcomes were reported.
3. Results
3.1. Search results
The search returned 406 articles via the Cochrane Central Register of
Controlled Trials, 3294 articles via MEDLINE, and 91 via POPLINE. Three
articleswere identiﬁed through hand searches of reference lists. In total,
3794 titles and 858 abstracts were reviewed (Fig. 1). The full text of 196
articles was read. In total, 3777 studies were excluded.
3.2. Included studies
Seventeen studies—15 randomized trials and two cohort studies—from
12 countries met the inclusion criteria (Table 1). For four studies, only the
subpopulations of women with a PAC indication were included.
The studies came from countries where abortion care is legal and
accessible, aswell as from countrieswith legal restrictions or limited ac-
cess to abortion care. One article from Iran [28] speciﬁcally excludedﬁve
women who had had a self-induced abortion, but all other articles did
not distinguish between women who had experienced an unsafe, ille-
gal, or self-induced abortion and those with a spontaneous abortion or
fetal demise.
3.3. Study participants
A total of 1419 women were included, of whom 1154 (81.3%)
presented with intrauterine fetal demise, 113 (8.0%) presented with
ruptured membranes, and 152 (10.7%) had had an induced abortion.
All studies included women presenting with intrauterine fetal death,
and ﬁve studies [18,19,22,23,28] included women with rupturedmem-
branes. No studies includedwomenpresentingwith other potential PAC
diagnoses, such as retained placenta without fetal tissues, hemorrhage,
foreign body, infection, or other complications after second-trimester
abortion. In most studies, the mean pregnancy duration fell within the
mid to late second trimester (Table 1).
3.4. Risk of bias
The risk of bias was low in ﬁve randomized controlled trials, unclear
in another ﬁve, and high in the remaining ﬁve (Table 1). The two cohort
studies had a low risk of bias according to the Newcastle–Ottawa
scale (Table 1). Many studies were brief reports and did not con-
tain supporting information to adequately judge the risk of bias.
3.5. Interventions for uterine evacuation
Every study that met the inclusion criteria had a misoprostol treat-
ment group. Most studies [12–17,21,22,24,25] reported comparisons
of misoprostol dose, route, and interval. One study [18] compared out-
patient misoprostol administration with inpatient administration, and
another [27] compared saline-moistened and dry vaginal misoprostol.
Four studies compared misoprostol with misoprostol plus an adjunct
treatment such as oxytocin [19,28], osmotic dilators [20], and mifepris-
tone [26]. One study [23] compared misoprostol with oxytocin. No
study compared medical methods with D&E.
Fig. 1. Identiﬁcation and selection of studies for the systematic review of second-trimester postabortion care.
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Four studies [16,17,22,25] evaluating vaginal versus oral admin-
istration at comparable doses and intervals were combined for meta-
analysis (Fig. 2). The doses and frequencies of misoprostol were
100 μg every 4 hours [16,17], 200 μg every 6 hours [25], and 400 μg
every 8 hours after an initial loading dose of misoprostol of 800 μg vag-
inally [22]. The overall effect of the route of administrationwas strongly
in favor of vaginal misoprostol (P b 0.001) (Fig. 2).
One study [17] showed a higher rate of retained placenta at
60 minutes in the vaginal group than in the oral group (27% vs 6%;
P= 0.02). However, this rate did not differ in two studies [16,22], and
one study [25] did not include information about retained placenta or
other outcomes.
One study [16] compared sublingual and oral misoprostol. Sublin-
gual administration was associated with a signiﬁcantly shorter mean
induction-to-expulsion interval than was oral administration (10.5 ±
3.7 h vs 21.0 ± 10.5 h; P b 0.05). The rates of manual placental removal
did not differ (46% vs 54%).
The same study [16] compared vaginal and sublingual misoprostol.
The mean induction-to-expulsion interval after sublingual administra-
tion was similar to that after vaginal administration (10.5 ± 3.7 h vs
13.9 ± 5.1 h; P N 0.05). There was no difference in the rate of manual
placental removal (46% vs 54%).3.7. Misoprostol dose
Two studies [12,24] compared misoprostol doses using comparable
intervals and routes of administration. One [12] compared 200 μg buccal
misoprostol every 6 hours with 100 μg, whereas the other [24] compared
600 μg vaginally given every 12 hours with 400 μg. Both of these studies
demonstrated faster expulsion times with higher doses of misoprostol.In the study of buccal misoprostol [12], the higher dose had a
reduced mean fetal and placental expulsion time (18.5 h vs 23.9 h;
P=0.02), and improved rates of expulsionwithin 24 hours of induction
(64.9% vs 39.5%; P=0.002) and within 48 hours of induction (77.9% vs
61.8%; P=0.03). Therewas a signiﬁcant increase in the frequency of di-
arrhea among women using 200 μg (32.5% vs 10.7%; P = 0.001), but
other adverse effects (e.g. nausea, vomiting, chills, headache, and
pain) were similar. Women in the 100-μg group were less satisﬁed
with the procedure, duration of treatment, and length of hospitalization
than were women given 200 μg.
In the study of vaginal misoprostol [24], the mean induction-to-
expulsion interval was shorter in the 600-μg group than in the 400-μg
group (9.2 ± 6.7 h versus 12.2 ± 7.7 h; P = 0.003). Adverse effects
did not differ signiﬁcantly between the two groups.3.8. Misoprostol dosing interval
One study [21] compared 200 μg misoprostol given vaginally every
6 hours versus every 12 hours. The mean induction-to-expulsion inter-
vals did not differ (13.8 h vs 14.0 h; P N 0.05). The 24-hour and 48-hour
success rates, incomplete abortion rates, and adverse effect rates also
did not differ.3.9. Heterogeneous comparisons of misoprostol route, dose, and interval
Three studies of misoprostol [13–15] could not be used to form
conclusions because the comparisons of dose, route, and interval were
heterogeneous. It was unclear what role the dose, loading dose, route,
or dosing interval played in the reported outcome. In all three studies,
higher cumulative doses irrespective of route were superior to lower
doses.
Table 1
Study details.
First author,
year
[reference]
Study design Location Treatment groups Number of participants Pregnancy
duration,
wka
Risk of
biasb
Total Induced
abortion
Fetal
death
Ruptured
membranes
Bracken, 2014 [12] RCT Vietnam, USA 100 μg vs 200 μg buccal misoprostol q6h 153 0 153 0 18 (14–28) Low
Chittacharoen, 2003 [13] RCT Thailand 400 μg oral misoprostol q4h vs 200 μg vaginal
misoprostol q12h
80 0 80 0 23 (16–41) Low
Dickinson, 2002 [14]c RCT Australia 200 μg vaginal misoprostol q6h vs 400 μg vaginal
misoprostol q6h vs 600 μg loading dose vaginal
misoprostol then 200 μg vaginal misoprostol q6h
36 0 36 0 18 (14–30) Low
Edward, 2005 [15]c Retrospective
cohort
USA 200 μg vaginal misoprostol q12h vs 400 μg vaginal
misoprostol q6h
29 0 29 0 20 (13–27) Low (7)
Elhassan, 2008 [16] RCT Sudan 100 μg vaginal misoprostol q4h vs 100 μg sublingual
misoprostol q4h vs 100 μg oral misoprostol q4h
150 0 150 0 18 (13–28) High
Fadalla, 2004 [17] RCT Sudan 100 μg vaginal misoprostol q4h vs 100 μg oral
misoprostol q4h
70 0 70 0 23 (13–28) Unclear
Gonzalez, 2001 [18] RCT USA 200 μg vaginal misoprostol q6h in hospital vs 200 μg
vaginal misoprostol q6h at home after ﬁrst dose
87 33 36 18 18 (13–28) Unclear
Hidar, 2001 [19] RCT Tunisia 200 μg vaginal misoprostol q12h vs 200 μg vaginal
misoprostol q12h with 15 mIU/min oxytocin
83 15 49 19 20 (13–29) Unclear
Jain, 1996 [20]c RCT USA 200 μg vaginal misoprostol with or without laminaria
at start of induction
38 0 38 0 16 (12–22) Unclear
Jain, 1999 [21] RCT USA 200 μg vaginal misoprostol q12h vs q6h 84 32 52 0 17 (12–22) Unclear
Kurshid, 2009 [22] RCT India 800 μg loading dose vaginal misoprostol then 400 μg
vaginal misoprostol q8h vs 800 μg loading dose vaginal
misoprostol then 400 μg oral misoprostol q8h
100 25 51 24 22 (19–23) High
Nakintu, 2001 [23] RCT Uganda 50 μg vaginal misoprostol doubled every 6 h vs
intravenous oxytocin to maximum dose 40 mIU/min
120 0 120 0 25 (18–40) Low
Niromanesh, 2005 [24] RCT Iran 400 μg vs 600 μg vaginal misoprostol q12h 100 0 100 0 NS (14–25) High
Nyende, 2004 [25] RCT South Africa 200 μg vaginal misoprostol q6h vs 200 μg oral
misoprostol q6h
38 0 38 0 28 (NS) High
Stibbe, 2012 [26]c Retrospective
cohort
Netherlands 200 μg oral misoprostol q3h vs 200 mg oral mifepristone
then 200 μg oral misoprostol q3h 36 h later
50 0 50 0 26 (17–40) Low (7)
Yilmaz, 2007 [27] RCT Turkey 800 μg dry vaginal misoprostol q6h × 3 dry vs moistened 81 36 45 0 20 (14–24) Low
Zageneh, 2012 [28] RCT Iran 600 μg loading dose vaginal misoprostol then 400 μg
vaginal misoprostol q6h vs 600 μg loading dose vaginal
misoprostol then intravenous oxytocin
120 11 57 52 17 (14–25) High
Abbreviations: RCT, randomized controlled trial; q6h, every 6 hours; q4h, every 4 hours; q12h, every 12 hours; q8h, every 8 hours; NS, not stated; q3h, every 3 hours.
a Values are given as mean (range).
b Cohort studies have the Newcastle–Ottawa score in parentheses.
c Substudy.
101A.G. Mark et al. / International Journal of Gynecology and Obstetrics 129 (2015) 98–1033.10. Addition of oxytocin to misoprostol
Two studies [19,28] compared oxytocin added tomisoprostol versus
misoprostol only. In theﬁrst study [28], all womenhad a loading dose of
600 μg vaginalmisoprostol andwere then randomized to receive 400 μg
misoprostol every 6 hours or concentrated oxytocin. No differences in
the mean induction-to-expulsion time were found with misoprostol
plus oxytocin versus misoprostol only (12.3 ± 6.0 h vs 12.1 ± 6.0 h;
P N 0.05). Adverse effects were also not different between the two
groups. In the second study [19], among women receiving misoprostol
200 μg every 12 hours, the addition of oxytocin at a rate of 15 mIU/min
starting with the ﬁrst misoprostol dose decreased the mean expulsion
time (22.1 ± 10.8 h v 27.1 ± 14.1 h; P b 0.05), but the rates of fetalFig. 2.Meta-analysis of difference in time from induction to abortion with vagiexpulsion at 48 hours, complete expulsion (fetus and placenta),
and adverse effects were similar between the two groups. These
two studies were not combined for meta-analysis because of their
heterogeneous designs.
3.11. Addition of mifepristone to misoprostol
One cohort study [26] evaluated women treated with 200 μg miso-
prostol vaginally every 3 hours alone, and a subsequent cohort treated
with mifepristone given 24–48 hours before misoprostol dosing.
Women with intrauterine fetal demise who had mifepristone pretreat-
ment had shorter induction-to-expulsion times than did women who
received misoprostol alone (10.6 h vs 16.2 h; P = 0.04). Mifepristonenal versus oral misoprostol, in hours. Abbreviation: CI, conﬁdence interval.
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the need for pain relief (P = 0.022). The risks of hemorrhage,
retained placenta, and surgery were not different between the two
groups.
3.12. Addition of laminaria to misoprostol
One study [20] randomized women to receive laminaria or no inter-
vention before undergoing misoprostol induction for fetal demise
with 200 μg vaginal misoprostol every 12 hours. The induction-to-
expulsion time was similar in the group receiving misoprostol only
and the group receiving misoprostol plus laminaria (15.7 h vs 17.4 h;
P=0.54). Adverse effects (including vomiting, diarrhea, fever, andmod-
erate pain)were similar in the twogroups, but the rate of severe painwas
higher amongwomen treatedwith laminaria (15.2% vs 34.3%; P=0.09).
3.13. Comparison of dry and moistened misoprostol
One randomized controlled trial [27] compared dry misoprostol
(800 μg vaginally) every 6 hours with moistened misoprostol (800 μg
vaginally) every 6 hours. There was no difference in the induction-to-
expulsion time or adverse effects between the two groups.
3.14. Comparison of home use to in-hospital misoprostol
One randomized trial [18] evaluated beginningmisoprostol at home
versus the hospital. One group of women was hospitalized and treated
with 200 μg of misoprostol vaginally every 6 hours until expulsion,
whereas the second group was instructed on self-insertion at home,
with instructions to return to the hospital when bleeding or contrac-
tions occurred, or when 24 hours had elapsed. Expulsion times in the
home and hospital groups did not differ (14.0 h vs 12.0 h; P = 0.28),
but the home administration group spent less time in the hospital
(11 h vs 24 h; P b 0.05). There were two extramural deliveries without
complications in the home group. All women favored the privacy and
intimacy of home use.
3.15. Comparison of misoprostol with oxytocin alone
One randomized trial [23] compared oxytocin alone with
misoprostol alone for women presenting with fetal death at more
than 18 weeks of pregnancy. The oxytocin dose was increased
every 30 minutes until contractions started or until a maximum
dose of 40 mIU/min was reached. Vaginal misoprostol was started
at 50 μg, and was doubled for each subsequent dose; doses were
given every 6 hours. The maximum misoprostol dose was 750 μg. The
induction-to-abortion time was signiﬁcantly shorter among women
who received misoprostol than among those receiving oxytocin
(12.4 h vs 23.3 hours; P= 0.004).
3.16. Other outcomes of interest
Only one study [14] stated that women with a history of cesar-
ean delivery were not excluded. Of the remainder, seven studies
[12,16,20–22,25,27] excluded women with a previous cesarean
delivery, one study [13] excluded women with classic cesarean de-
livery only, three studies [17,19,28] excluded women with more
than one cesarean delivery, and ﬁve studies [15,18,23,24,26] did
not specify whether women with a previous cesarean delivery
were excluded.
There was one report [14] of hysterectomy for hemorrhage
and placenta accreta in a woman with four previous cesarean de-
liveries after using vaginal misoprostol. There were no reported
uterine ruptures.4. Discussion
Overall, the present review has shown that the published literature
lacks comparable, high-quality data on the management of PAC in the
second trimester. There were limited data available for meta-analysis.
However, several patterns emerge from the present review to guide
clinical practice. First, misoprostol given either vaginally or sublingually
is more effective than oral misoprostol. Second, misoprostol doses at or
above 200 μg decrease the induction-to-expulsion time, but the maxi-
mum dose based on the risk of adverse effects or adverse outcomes is
not known. Third, pretreatment with mifepristone may decrease the
overall induction-to-expulsion time. Finally, misoprostol is associated
with a shorter time to expulsion than oxytocin alone. These ﬁndings
are analogous to those observed for managing induced abortion in the
second trimester [28].
Non-oral (vaginal, sublingual, and possibly buccal) routes of miso-
prostol administration are more effective than is the oral route at the
same doses. The present review conﬁrmed that vaginal and sublingual
misoprostol are more effective than is oral misoprostol. One study [12]
used buccal dosing in both groups without comparison with other
routes. Given the efﬁcacy of buccal misoprostol in induced abortion in
the ﬁrst [29] or second [30] trimester and the similar uterotonic proﬁle
to vaginal dosing [31], buccal dosing seems appropriate.
In both studies that comparedmisoprostol dosing [12,24], higher doses
of misoprostol had shorter induction-to-abortion intervals than did lower
doses. Given the superiority of the 200-μg dose over the 100-μg dose in
one high-quality trial [12], misoprostol doses of 200 μg or more are likely
to have shorter induction-to-abortion intervals than lower doses. The
optimal dose, with which the risk of adverse effects is outweighed by the
beneﬁt of the shortened induction interval, is not yet established. In
addition, as pregnancy advances into the late second trimester, lower
doses of misoprostol could be used to achieve the same effect. In the
included studies, the risk of adverse effects was not systematically
evaluated and none of the studies was adequately powered to detect
differences in serious adverse events. The recommended misoprostol
dose for induced abortion in the second trimester is 400 μg [2]. This dose
could be appropriate for PAC as well and should be studied further.
The only article [21] designed to compare the dosing interval
showed no difference in the induction-to-delivery time between
6-hourly and 12-hourly doses. In other studies [16,17,26], dosing
intervals of less than 6 hours were used but not compared. The
recommended dosing interval for induced abortion is 3 hours, which
has improved outcomes when compared with 6-hourly dosing [32].
The addition of pretreatment with mifepristone would be expected
to improve outcomes, on the basis of evidence from studies of induced
abortion [32]. In the present review, this notion was supported by one
small study in women with fetal demise [26]. More research is needed
on this promising intervention. In women who do not require immedi-
ate intervention, mifepristone could be beneﬁcial.
Other interventions—e.g. moistening the misoprostol tablets,
adding oxytocin to misoprostol, giving misoprostol at home, or adding
laminaria—did not improve outcomes but could impact women’s expe-
rience and satisfaction with care.
No studies compared D&E with medical methods of uterine evac-
uation or D&E variations (e.g. different surgical techniques or
cervical preparation agents) in the PAC population. Dilation and
evacuation is a WHO-recommended method for uterine evacuation
in the second trimester [2]. Because D&E compares favorably with
medical induction for second-trimester induced abortion, women
could be offered D&E for PAC when skilled providers and supportive
facilities are in place [33].
The strength of the present review is the inclusion of studies from
multiple countries. Because studies were included from countries with
restricted abortion access, the review is likely to include women pre-
senting with intrauterine demise or rupture of membranes after unsafe
or self-induced abortion.
Box 1
Recommendations for second-trimester postabortion care.
The following recommendations are made on good and consistent
scientific evidence (Grade A):
• Misoprostol should be used in preference to oxytocin alone.
• Vaginal or sublingual administration ofmisoprostol is superior
to oral administration.
The following recommendations are made on limited or inconsis-
tent scientific evidence (Grade B):
• Misoprostol should be given at a dose of at least 200 μg.
• The frequency of misoprostol dosing should be at least every
6 hours.
• When available and time permitting, mifepristone should be
used before misoprostol.
• Osmotic dilators should not be used.
The following recommendations are based primarily on expert
opinion (Grade C):
• Buccal administration of misoprostol can be used.
• Where skilled providers and supportive facilities exist, dilation
and evacuation could be offered.
103A.G. Mark et al. / International Journal of Gynecology and Obstetrics 129 (2015) 98–103The limitations of the present review are the lack of systematic
investigation, the heterogeneous nature of the interventions, the
quality of the included studies, and the small number of women.
The low quality of the studies meant adverse effects were not consis-
tently measured or reported. Because of the low numbers, rare seri-
ous adverse events could not be assessed. Moreover, D&E could not
be evaluated.
In conclusion, misoprostol with or without mifepristone is an
effective medical treatment for women presenting for second-
trimester PAC. Women with indications including fetal demise or
ruptured membranes should be treated with misoprostol vaginally,
sublingually, or buccally according to the evidence generated by
the review (Box 1). More research is needed to see if recommended
regimens for second-trimester induced abortion can be used for
women who need PAC [2]; however, the evidence indicates that
these regimens would be acceptable.
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